Home > Insider Trading > Filing (0001225208-20-011150)

Filing Details

Accession Number:: 0001225208-20-011150
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-09-01 20:26:30
Reporting Period:: 2020-08-28

Accepted Time:: 2020-09-01 20:26:30
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1088856	Corcept Therapeutics Inc	CORT	Pharmaceutical Preparations (2834)	770487658

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1201715	Jr Leonard G Baker	755 Page Mill Road, Suite A-200 Palo Alto CA 94304-1005		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-08-28	20,444	$12.48	3,135,237	No	4	P	Indirect	By Ltd Partnership
Common Stock	Acquisiton	2020-09-01	25,807	$12.50	3,161,044	No	4	P	Indirect	By Ltd Partnership

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Ltd Partnership
No	4	P	Indirect	By Ltd Partnership

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	996,838	Direct
Common Stock	955,055	Indirect	By Trust

Footnotes

The purchases reported in this Form 4 were matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, with the sales of shares by the reporting person, to the extent of the reporting person's pecuniary interest therein, at prices ranging from $15.76 to $15.7602, inclusive, on May 28, 2020. The reporting person has agreed to pay to the Issuer the profit realized by the reporting person in connection with the short-swing transaction, less transaction costs.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.43 to $12.50, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the general partner. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.45 to $12.50, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
The reporting person shares pecuniary interest in these shares with other individuals pursuant to a contractual relationship. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares.
Shares held by a trust of which the reporting person is a trustee. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in the trust.